Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 1, 2013, Pages 48-54

  Guin, Aharna ^a   Chatterjee Adhikari, Maitrayee ^a   Chakraborty, Sumit ^a   Sinhamahapatra, Pradyot ^a   Ghosh, Alakendu ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Atherosclerosis; Carotid intima media thickness (cIMT); Disease modifying anti rheumatic drugs (DMARDs); Early rheumatoid arthritis; Endothelial dependent flow mediated vasodilatation (ED FMD); Endothelial dysfunction (ED)

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE DURATION; DRUG DOSE TITRATION; ECHOGRAPHY; ENDOTHELIAL DEPENDENT FLOW MEDIATED VASODILATATION; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNOVITIS; VASODILATATION;

ATHEROSCLEROSIS; CAROTID INTIMA-MEDIA THICKNESS (CIMT); DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS); EARLY RHEUMATOID ARTHRITIS; ENDOTHELIAL DEPENDENT FLOW-MEDIATED VASODILATATION (ED-FMD); ENDOTHELIAL DYSFUNCTION (ED);

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; BRACHIAL ARTERY; CAROTID INTIMA-MEDIA THICKNESS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84881552797     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.12.027     Document Type: Article

References (49)

1. Wolfe F., Mitchell D.M., Sibley J.T., Fries J.F., Bloch D.A., Williams C.A., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994, 37:481-494.
2. Solomon D.H., Karlson E.W., Rimm E.B., Cannuscio C.C., Mandl L.A., Manson J.E., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303-1307.
3. Maradit-Kremers H., Nicola P.J., Crowson C.S., Ballman K.V., Gabriel S.E. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52:722-732.
4. Van Doornum S., Mc Coll G., Wicks I.P. Accelerated atherosclerosis: an extra-articular feature of rheumatoid arthritis?. Arthritis Rheum 2002, 46:862-873.
5. Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M.M., Ronda N., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005, 112:3337-3347.
6. Nurmohamed M.T., Kitas G. Editorial. Cardiovascular risk in rheumatoid arthritis and diabetes: how does it compare and when does it start?. Ann Rheum Dis 2011.
7. Lindhardsen J., Ahlehoff O., Gislason G.H., Madsen O.R., Olesen J.B., Torp-Pedersen C., et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011, 70:929-934.
8. Van Doornum S., Jennings G.L., Wicks I.P. Reducing the cardiovascular disease burden in rheumatoid arthritis. Med J Aust 2006, 184:287-290.
9. Dessein P.H., Joffe B.I., Veller M.G., Stevens B.A., Tobias M., Reddi K., et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005, 32:435-442.
10. McEntegart A., Capell H.A., Madhok R. Predicting coronary risk in rheumatoid arthritis. Arthritis Rheum 2001, 44:S53.
11. van Vliet-Daskalopoulou E., Jentjens T., Scheffer R.T. Intra-articular rimexolone in the rheumatoid knee: a placebo-controlled, double blind, multicentre trial of three doses. Br J Rheumatol 1987, 26:450-453.
12. Hills B.A., Ethell M.T., Hodgson D.R. Release of lubricating synovial surfactant by intra-articular steroid. Br J Rheumatol 1998, 37:649-652.
13. Georgiadis A.N., Voulgari P.V., Argyropoulou M.I., Alamanos Y., Elisaf M., Tselepis A.D., et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 2008, 38:13-19.
14. Hannawi S., Haluska B., Marwick T.H., Thomas R. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 2007, 9:R116.
15. Hannawi S., Marwick T.H., Thomas R. Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 2009, 11:R51.
16. Adhikari M.C., Guin A., Chakraborty S., Sinhamahapatra P., Ghosh A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum 2012, 41(5):669-675.
17. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257-265.
18. Bots M.L., Westerink J., Rabelink T.J., de Koning E.J. Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J 2005, 26:363-368.
19. Persson J., Stavenow L., Wikstrand J., Israelsson B., Formgren J., Berglund G. Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size. Arterioscler Thromb 1992, 12:261-266.
20. Van Der Kooji S.M., Allaart C.F., Dijkmans B.A., Breeveld F.C. Innovative treatment strategies for patients with rheumatoid arthritis. Curr Opin Rheumatol 2008, 20:287-294.
21. Möttönen T., Hannonen P., Leirisalo-Repo M., Nissilä M., Kautiainen H., Korpela M., et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. Lancet 1999, 353(9164):1568-1573.
22. Anderson J.J., Wells G., Verhoeven A.C., Felson D.T. Factors predicting response to treatment in rheumatoid arthritis: the importance of the disease duration. Arthritis Rheum 2000, 43(1):22-29.
23. Calgüneri N., Pay S., Caliskaner Z., Apras S., Kiraz S., Ertenli I., et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999, 17(6):699-704.
24. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59(6):762-784.
25. van Halm V.P., Nurmohamed M.T., Twisk J.W.R., Dijkmans B.A.C., Voskuyl A.E. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006, 8:R151.
26. Quyyumi A.A. Inflamed joints and stiff arteries: is rheumatoid arthritis a cardiovascular risk factor?. Circulation 2006, 114:1137-1139.
27. Westlake S.L., Colebatch A.N., Baird J., Kiely P., Quinn M., Choy E., et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010, 49:295-307.
28. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
29. Bruce B., Fries J. The Stanford health assessment questionnaire (HAQ): a review of its history, issues, progress, and documentation. J Rheumatol 2003, 30(1):167-178.
30. Prevoo M.L., Van't Hof M.A., Kuper H.H., Van Leeuwen M.A., L.B.Van De Putte, van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
31. Turesson C., Jarenros A., Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004, 63:952-955.
32. Haque S., Mirjafari H., Bruce I.N. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr Opin Lipidol 2008, 19:338-343.
33. John H., Kitas G., Toms T., Goodson N. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009, 23:71-82.
34. Quinn M.A., Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003, 21:S154-S157.
35. Choi H.K., Hernan M.A., Seeger J.D., Robins J.M., Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177.
36. Tabit C.E., Holbrook M., Shenouda S.M., Dohadwala M.M., Widlansky M.E., Frame A.A., et al. Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease. Vasc Med 2012, 17(2):101-107.
37. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
38. Sherer Y., Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nature Clin Practice Rheumatol 2006, 2:99-106.
39. Kerekes G., Szekanecz Z., Dér H., Sándor Z., Lakos G., Muszbek L., et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008, 35(3):398-406.
40. Solmaz D., Sari I., Can G., Akar S., Ceylan I., Secil M., et al. The effect of non-steroidal anti-inflammatory drugs on the endothelial function of patients with osteoarthritis in short term. Int J Rheum Dis 2012, 15(2):207-211.
41. Georgiadis A.N., Papavasiliou E.C., Lourida E.S., Alamanos Y., Kostara C., Tselepis A.D., et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res Ther 2006, 8:R82.
42. Boers M., Nurmohamed M.T., Doelman C.J.A., Lard L.R., Verhoeven A.C., Voskuyl A.E., et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:842-845.
43. Park Y.B., Choi H.K., Kim M.Y., Lee W.K., Song J., Kim D.K., et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002, 113:188-193.
44. Dessein P.H., Joffe B.I., Stanwix A.E. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 2002, 4:R12.
45. Scott D.L. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 2012, 91(1):30-43.
46. Emery P., McInnes I.B., van Vollenhoven R., Kraan M.C. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:392-398.
47. Hürlimann D., Forster A., Noll G., Enseleit F., Chenevard R., Distler O., et al. Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106:2184-2187.
48. Irace C., Mancuso G., Fiaschi E., Madia A., Sesti G., Gnasso A. Effect of anti TNF-α therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004, 177:113-118.
49. McCarey D., McInnes I.B., Madhok R., Hampson R., Scherbakova O., Ford I., et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 2004, 363:2015-2021.